Ikaros (<i>IKZF1</i>) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood <i>BCR</i>/<i>ABL</i>‐negative acute lymphoblastic leukemia

Abstract

We show that MRD-directed treatment diminishes prognostic impact of IKZF1 alterations. However, IKZF1 status alone or combined with day 15 flow cytometry can significantly improve risk stratification within BFM protocols at centers that do not perform antigen-receptor-based MRD monitoring.